Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia

Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O’Brien, Hagop Kantarjian, Farhad Ravandi We reviewed 301 patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) who presented from January 2000 to January 2014 (183, t-AML without antecedent hematologic disorders [AHD]; 118, t-AML with AHD). Overall, median follow-up was 44 months. The primary malignancy was non-Hodgkin lymphoma in 92 (31%); breast cancer in 80 (27%); and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months, and 29 months, respectively (p=0.032): median overall survival (OS) was 8 months, and 8 months, respectively (p=0.53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, non-favorable cytogenetics, and lack of response as adverse factors. The favorable risk cohort had better RFS and OS as compared to the outcomes of patients in the intermediate and adverse risk cohorts; the RFS and OS did not differ between intermediate and adverse cohorts. The presence of AHD did not affect OS. Teaser Microabstract: The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival. The favorable risk ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research